Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma

Date
2017
Authors
Senses, K. M.
Ghasemi M.
Akbar, M. W.
Isbilen, M.
Fallacara, A. L.
Frankenburg, S.
Schenone, S.
Lotem, M.
Botta, M.
Gure, A. O.
Editor(s)
Advisor
Supervisor
Co-Advisor
Co-Supervisor
Instructor
Source Title
MedChemComm
Print ISSN
2040-2503
Electronic ISSN
Publisher
Royal Society of Chemistry
Volume
8
Issue
1
Pages
88 - 95
Language
English
Journal Title
Journal ISSN
Volume Title
Series
Abstract

Transcriptomic phenotypes defined for melanoma have been reported to correlate with sensitivity to various drugs. In this study, we aimed to define a minimal signature that could be used to distinguish melanoma sub-types in vitro, and to determine suitable drugs by which these sub-types can be targeted. By using primary melanoma cell lines, as well as commercially available melanoma cell lines, we find that the evaluation of MLANA and INHBA expression is as capable as one based on a combined analysis performed with genes for stemness, EMT and invasion/proliferation, in identifying melanoma subtypes that differ in their sensitivity to molecularly targeted drugs. Using this approach, we find that 75% of melanoma cell lines can be treated with either the MEK inhibitor AZD6244 or the HSP90 inhibitor 17AAG.

Course
Other identifiers
Book Title
Citation
Published Version (Please cite this version)